Search Within

Heiko Schoder

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (23)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (59)
  2. Department of Medicine (59)
  3. Hematologic Malignancies, Division of (59)
  4. Lymphoma (59)
  5. Molecular Imaging and Therapy Service (59)
  6. Radiology, Department of (59)

More Groups

People
  1. Alison Moskowitz (59)
  2. Andrew Zelenetz (43)
  3. Paul Hamlin (41)
  4. Steven Horwitz (41)
  5. Anita Kumar (39)
  6. Ariela Noy (39)

More People

Years
  1. 2025 (1)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (5)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Blood (25)
  2. Hematological Oncology (7)
  3. Journal of Clinical Oncology (6)
  4. Blood Advances (4)
  5. Haematologica (3)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. Wiley Blackwell (7)
  3. American Society of Clinical Oncology (6)
  4. Ferrata Storti Foundation (3)
  5. Elsevier Science, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (59)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study
    Meeting Abstract

    Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information
    Journal Article

    Nakajima, R.; Moskowitz, A. J.; Michaud, L.; Mauguen, A.; Batlevi, C. L.; Dogan, A.; Schöder, H.
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information
    Meeting Abstract

    Nakajima, R.; Moskowitz, A. J.; Michaud, L.; Mauguen, A.; Schöder, H.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save
  • Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
    Journal Article

    Mehta-Shah, N.; Ito, K.; Bantilan, K.; Moskowitz, A. J.; Sauter, C.; Horwitz, S. M.; Schöder, H.
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save